Review: Aldosterone — the future challenge in cardiovascular disease?

Abstract

Mineralocorticoid receptor activation plays a key role in cardiovascular disease and hypertension, which are particularly prevalent in diabetes mellitus; secondary hyperaldosteronism contributes to cardiac failure. Major intervention trials in heart failure have demonstrated unequivocal benefit from aldosterone receptor antagonism. Focused experimental studies in humans and in animal models of hypertension have shown that aldosterone blockade improves a number of pathogenic abnormalities including vascular endothelial dysfunction and altered baroreflex function, and prevents the development of cardiac hypertrophy and renal histological damage. Based on recent outcomes studies, the challenge is now to transfer the experimental evidence into clinical M practice.

Keywords

aldosterone spironolactone eplerenone angiotensin receptor antagonist.

Get full access to this article

View all access options for this article.

References

Petersen S. , Peto V. , Rayner M. (2003) Coronary Heart Disease Statistics. Oxford: British Heart Foundation Health Promotion Research Group.

National Library of Medicine and the National Institutes of Health. Medical Encyclopedia. Available at http://www.nlm.nih.gov/medlineplus/encyclopedia.html (Date accessed 15 October 2003).

Department of Health. (2001) National Service Framework for Diabetes - National Service Framework for Diabetes Standards. London: Department of Health.

Stamler J. , Vaccaro O. , Neaton JD , Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.

British Heart Foundation Health Promotion Research Group. (2003) Coronary Heart Disease Statistics - British Heart Foundation Statistics Database 2003. London: British Heart Foundation.

Davies JO , Freeman RH Historical perspectives on the renin-angiotensin-aldosterone system and angiotensin blockade. Am J Cardiol 1982 ; 49:1385-9.

Mortensen RM , Williams GH Aldosterone action in: DeGroot LJ , Jameson JL , eds. Endocrinology, 4th edition. WB Saunders, Philadelphia, PA, 2001:1783-9.

Wehling M. Aldosterone specific membrane receptors, rapid activation of the sodium-hydrogen exchanger, and cardiovascular implications. Cardiovasc Res 1995;29:167-71.

Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994;24:571-5.

10.

Schmidt BMW , Montealegre A. , Janson CP et al. Short term cardiovascular effects of aldosterone in healthy male volunteers. J Endocrinol Metab 1999;84:3528-33.

11.

Brilla CG , Matsubara LS , Weber KT Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldo teronism. J Mol Cell Cardiol 1993;25:563-75.

12.

Schachter M. Aldosterone antagonism: new ideas, new drugs . Br J Cardiol 2002;9:533-7.

13.

Gómez-Sánchez EP , Venkataraman MT , Thwaites D. , Fort C. ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am J Physiol 1990;258:E649-E653.

14.

Tanabe A. , Naruse M. , Naruse K. et al. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension . Hypertens Res 1997;20:8590.

15.

Rocha R. , Stier CT Jr , Kifor I. et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy . Endocrinology 2000;141:3871-8.

16.

Rocha R. , Chander PN , Khanna K. et al. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertens 1998;31:451-8.

17.

Sun Y. , Zhang J. , Lu L. Aldosterone-induced inflammation in the rat heart: role of oxidative stress . Am J Pathol 2002;161:1773-81.

18.

Struthers AD Pathophysiology of aldosterone and its antagonists . Fundam Clin Pharmacol 2000;14:549-52.

19.

MacFayden RJ , Barr CS , Struthers AD Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart failure patients. Cardiovasc Res 1997 ;35:30-4.

20.

Duprez DA , De Buyzere ML , Rietzschel ER et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998;19:1371-6.

21.

Yamamoto K. , Burnett JC , Jougasaki M. et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996 ;28:988-94.

22.

Weber KT , Villarreal D. Aldosterone and antialdosterone therapy in congestive heart failure . Am J Cardiol 1993;71:3A-11A.

23.

Cleland JGF , Dargie HJ , Hodsman GP Captopril in heart failure. A double blind controlled trial. Br Heart J 1984;52:530-5.

24.

Staessen J. , Lijnen P. , Fagard R. et al. Rise in plasma concentration of aldosterone during long-term angiotensisn II suppression . J Endocrinol 1981;91:457-65.

25.

McKelvie RS , Yusuf S. , Pericak D. et al. for the RESOLVD Pilot Study Investigators. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Circulation 1999;100:1056-64.

26.

The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325(5):293-302.

27.

CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial . Lancet 1999;353:9-13.

28.

Burnier M. , Brunner HR Angiotensin II receptor antagonists. Lancet 2000;355:637-45.

29.

Pfeffer MA , Swedberg K. , Granger CB Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66.

30.

Pitt B. `Escape' of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995;9:145-9.

31.

Pitt B. , Zannad F. , Remme WJ et al. for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.

32.

Pitt B. , Remme W. , Zannad F. et al. for the Eplerenone Post-Acute MI Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after MI. N Engl J Med 2003;348:1309-21.

33.

Primatesta P. , Brookes M. , Poulter NR

Improved hypertension management and control - results from the Health Survey for England

1998. Hypertens 2001;38:827-32.

34.

Hiramatsu K. , Yamada T. , Yukimura Y. et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients . Arch Intern Med 1981;141:1589-93.

35.

Lim PO , Jung RT , MacDonald TM Is aldosterone the missing link in refractory hypertension?: aldosterone-to-renin ratio as a marker of inappropriate aldosterone activity. J Hum Hypertens 2002;16:153-8.

36.

Connell JMC , Fraser R. , MacKenzie S. , Davies E.

Is altered adrenal steroid biosynthesis a key intermediate phenotype in hypertension?

Hypertension 2003;41:993-9.

37.

Lim PO , Jung RT , MacDonald TM Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol 1999;48:756-60.

38.

Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertension 2004;18:139-85. ( www.bhsoc.org).

39.

Lim PO , Young WF , MacDonald TM A review of the medical treatment of primary aldosteronism. J Hypertens 2001;19:353-61.

40.

Foo R. , O'Shaughnessy M. , Brown MJ Hyperaldosteronism: recent concepts, diagnosis and management. Postgrad Med J 2001;77:639-44.

41.

Lim PO , Jung RT , MacDonald TM Raised aldosterone to rennin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol 1999;48:756-60.

42.

Stier CT , Koenig S. , Lee DY et al. Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone. Heart Dis 2003;5: 102-18.

43.

Coleman CI , Reddy P. , Song JC et al. Eplerenone: the first selective aldosterone receptor antagonist for the treatment of hypertension. Formulary 2002;37:514-24.

44.

Anonymous. Eplerenone (Inspra) . Med Lett Drugs Ther 2003; 45(1156):39-40.

45.

Weber MA Clinical implications of aldosterone blockade. Am Heart J 2002;144:S12-S18.

46.

White WB , Duprez D. , St Hillaire R. et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41:1021-6.

47.

Krum H. , Nolly H. , Workman D. et al. Efficacy of eplerenone added to rennin-angiotensin blockade in hypertensive patients. Hypertension 2002 ;40:117-23.

48.

Moore TD , Nawarskas JJ , Anderson JR Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. Heart Dis 2003;5:354-63.

49.

Domenic A. , Sica MD Eplerenone: a new aldosterone receptor antagonist - are the FDA's restrictions appropriate? J Clin Hypertens 2002; 4(6):441-5.

50.

Haffner SM , Lehto S. , Rónnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior MI. N Engl J Med 1998;339:229-34.

51.

The Hypertension in Diabetes Study Group. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993;11:309-17.

52.

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.

53.

Hansson L. , Zanchetti A. , Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998 ;351:1755- D62.

54.

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.

55.

Yusuf S. , Sleight P. , Pogue J. et al. for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.

56.

Lewis EJ , Hunsicker LG , Clarke WR et al. for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.

57.

Goodfriend TL , Kelley DE , Goodpaster BH , Winters SJ Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women . Obes Res 1999;7:355-62.

58.

Epstein M. , Buckalew V. , Martinez F. et al. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria. Am J Hypertens 2002;15 (4 part 2):24A. Abstract OR-54.

59.

White WB , Duprez D. , St Hillaire R. et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41:1021-6.